New Key Statistics Module, Z-Score and F-Score
NAS:CYTO Key Ratios
| Market Cap $ M | 1.62 |
| Enterprise Value $ M | 2.10 |
| P/E(ttm) | 0.90 |
| PE Ratio without NRI | 1.04 |
| Forward PE Ratio | -- |
| Price/Book | 0.18 |
| Price/Sales | 3.32 |
| Price/Free Cash Flow | 0.11 |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | 0.48 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 72.50 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.93 |
| EV-to-EBITDA | -0.96 |
| PEG | 0.01 |
| Shares Outstanding M | 3.78 |
| Net Margin (%) | -273.40 |
| Operating Margin % | -1,113.30 |
| Pre-tax Margin (%) | -1,091.49 |
| Quick Ratio | 0.43 |
| Current Ratio | 0.43 |
| ROA % (ttm) | -9.22 |
| ROE % (ttm) | -36.91 |
| ROIC % (ttm) | -37.48 |
| Dividend Yield % | -- |
| Altman Z-Score | -21.82 |
CYTO Number of Guru Trades
CYTO Volume of Guru Trades
Gurus Latest Trades with NAS:CYTO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CYTO is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Altamira Therapeutics Ltd Insider Transactions
No Available Data
News about NAS:CYTO
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers